WT1 Peptide

WT1,Wilms tumor 1 Peptide has a potential role in transcriptional regulation by recognizing and binding to the DNA sequence 5-CGCCCCCGC-3. Defects in WT1 are the cause of nephropathy (Frasier and Denys-Drash syndromes) and genito-urinary dysplasia in Wilms tumor syndrome.Data on WT1 peptide vaccine-treated patients with immunological and/or clinical response have been accumulated. MDS and acute myeloid leukemia were the major target diseases to provide proof of concept for the therapeutic potential of the WT1 peptide vaccine. WT1 vaccination-induced clinical responses or usefulness were also shown for chronic myeloid leukemia, multiple myeloma, and acute lymphoblastic leukemia, as well as various types of solid cancers.Patients with hematologic malignancies have minimal residual disease after chemotherapy or allogeneic hematopoietic stem cell transplantation, which can be treated by WT1 peptide vaccine.

MSDS of WT1 Peptide